Abstract: Objective：To evaluate the short-term efficacy and safety of anlotinib combined with chemotherapy in the treatment of advanced soft tissue sarcoma (STS). Methods：A total of 27 patients with advanced STS consisting of 11 leiomyosarcoma, 3 dedifferentiated liposarcoma, 3 synovial sarcoma, and 10 other types of STS, were treated with anlotinib plus chemotherapy. The anlotinib was combined with chemotherapy as the first-line treatment in 14 patients, and as second- or third-line treatment in 13 patients. Chemotherapy regimens were based on anthracyclines and ifosfamide, and other drugs included dacarbazine, gemcitabine, temozolomide, vincristine, cyclophosphamide, paclitaxel, and so on. Efficacy and safety were evaluated every 2 treatment cycles. Results：Among the 27 patients, 9 cases had partial response (PR), 10 cases had stable disease (SD), and 8 cases had progressive disease (PD). The overall response rate (ORR) was 33.3% (9/27), with a disease control rate (DCR) of 70.4% (19/27). The common treatment-related adverse effects included bone marrow suppression, nausea, vomiting, hypertension, and oral mucositis. One patient had severe adverse effect, which was febrile neutropenia. No treatment-related death was found. Conclusions：Anlotinib combined with chemotherapy in the treatment of advanced STS is effective and tolerable, which is a promising strategy. It is worthy of further clinical research.